MX2021001549A - Una composicion farmaceutica para el tratamiento seguro y efectivo del dolor de rodilla y/o cadera. - Google Patents

Una composicion farmaceutica para el tratamiento seguro y efectivo del dolor de rodilla y/o cadera.

Info

Publication number
MX2021001549A
MX2021001549A MX2021001549A MX2021001549A MX2021001549A MX 2021001549 A MX2021001549 A MX 2021001549A MX 2021001549 A MX2021001549 A MX 2021001549A MX 2021001549 A MX2021001549 A MX 2021001549A MX 2021001549 A MX2021001549 A MX 2021001549A
Authority
MX
Mexico
Prior art keywords
knee
pharmaceutical composition
hip pain
safe
hip
Prior art date
Application number
MX2021001549A
Other languages
English (en)
Spanish (es)
Inventor
Catherine Stehman-Breen
John Davis
Gregory Geba
Paula Dakin
Stephen Dimartino
Haitao Gao
Jennifer Maloney
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2021001549A publication Critical patent/MX2021001549A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2021001549A 2018-08-10 2019-08-09 Una composicion farmaceutica para el tratamiento seguro y efectivo del dolor de rodilla y/o cadera. MX2021001549A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862717435P 2018-08-10 2018-08-10
US201862764816P 2018-08-15 2018-08-15
PCT/US2019/045970 WO2020033872A1 (en) 2018-08-10 2019-08-09 A pharmaceutical composition for safe and effective treatment of knee and/or hip pain

Publications (1)

Publication Number Publication Date
MX2021001549A true MX2021001549A (es) 2021-04-13

Family

ID=67811008

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001549A MX2021001549A (es) 2018-08-10 2019-08-09 Una composicion farmaceutica para el tratamiento seguro y efectivo del dolor de rodilla y/o cadera.

Country Status (10)

Country Link
US (2) US11472870B2 (enExample)
EP (1) EP3833687A1 (enExample)
JP (1) JP7460598B2 (enExample)
KR (1) KR20210043624A (enExample)
CN (1) CN112839956A (enExample)
AU (1) AU2019318556A1 (enExample)
CA (1) CA3108697A1 (enExample)
IL (1) IL280550B2 (enExample)
MX (1) MX2021001549A (enExample)
WO (1) WO2020033872A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7532290B2 (ja) * 2021-03-09 2024-08-13 エヌ・ティ・ティ・コミュニケーションズ株式会社 患者追跡調査支援システム、患者追跡調査支援方法、支援制御装置、端末装置およびプログラム
EP4433500A1 (en) 2021-11-19 2024-09-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for reducing centralized pain
WO2023212586A1 (en) * 2022-04-27 2023-11-02 Regeneron Pharmaceuticals, Inc. Methods for selecting patients for treatment with an ngf antagonist

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
DK2270048T3 (en) 2002-12-24 2016-01-18 Rinat Neuroscience Corp Anti-NGF antibodies and methods for their use
ME00226B (me) * 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
MX2010001395A (es) 2007-08-10 2010-03-10 Regeneron Pharma Anticuerpos humanos de alta afinidad de factor de crecimiento de nervio humano.
US8309088B2 (en) * 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
AU2011227335B2 (en) * 2010-03-17 2014-11-06 Abbott Research B.V. Anti-nerve growth factor (NGF) antibody compositions
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
NZ609557A (en) 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
CA2875783C (en) * 2012-06-06 2018-12-11 Zoetis Llc Caninized anti-ngf antibodies and methods thereof
IL266640B (en) * 2016-11-29 2022-09-01 Regeneron Pharma A pharmaceutical composition for averting opioid addiction

Also Published As

Publication number Publication date
AU2019318556A1 (en) 2021-03-04
KR20210043624A (ko) 2021-04-21
JP2021533142A (ja) 2021-12-02
JP7460598B2 (ja) 2024-04-02
WO2020033872A1 (en) 2020-02-13
CN112839956A (zh) 2021-05-25
US20200048337A1 (en) 2020-02-13
CA3108697A1 (en) 2020-02-13
EP3833687A1 (en) 2021-06-16
IL280550B2 (en) 2025-06-01
IL280550A (en) 2021-03-25
IL280550B1 (en) 2025-02-01
US20220041708A1 (en) 2022-02-10
US11472870B2 (en) 2022-10-18

Similar Documents

Publication Publication Date Title
JOP20200031A1 (ar) طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة
CY1123688T1 (el) Μεθοδοι για τη θεραπευτικη αντιμετωπιση ογκων χρησιμοποιωντας αμφιειδικο αντισωμα cd3xcd20
MX2025000380A (es) Metodos de tratamiento con farmacos del sustrato cyp3a4
MX2020010603A (es) Extracto de cáñamo para tratamiento de dolor en animales.
MX2017005875A (es) Metodos para tratar enfermedades oculares.
MX389927B (es) Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.
AR109103A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
MX2021001549A (es) Una composicion farmaceutica para el tratamiento seguro y efectivo del dolor de rodilla y/o cadera.
MX2025003477A (es) Uso de reboxetina para el tratamiento de narcolepsia
PH12017500392A1 (en) Medical treatments based on anamorelin
BR112022013646A2 (pt) Método de tratamento de esplenomegalia
PH12020500032A1 (en) Isotretinoin oral-mucosal fromulations and methods for using same
EA202090242A1 (ru) Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов
MX2023015097A (es) Tratamiento de sintomas asociados a neoplasias mieloproliferativas.
MX2015013115A (es) Nuevos regimenes de dosificacion de celgosivir para el tratamiento de dengue.
MX375350B (es) Medicamento para el tratamiento de infecciones de pie diabetico
WO2020061067A8 (en) Compositions and methods for treating bone injury
MX2021000207A (es) Regímenes de dosificación para el tratamiento de daños en los tejidos asociados a la hipoxia.
EA202190294A1 (ru) Комбинированная терапия для лечения рака
EA202091744A1 (ru) Лечение аллергического ринита у субъектов детской возрастной категории с применением комбинации мометазона и олопатадина
HK1225969A1 (zh) 利用低剂量的拉喹莫德治疗克隆氏病
EA202190291A1 (ru) Комбинированная терапия для лечения рака
MX2023006765A (es) Metodo para proporcionar terapia de celiprolol a un paciente.
RU2014120624A (ru) Способ лечения инсульта
EA201900418A1 (ru) Средство для терапии раневых или ожоговых поражений кожи